Fig. 4

Akt inhibitor treatment reduces cIAP2 expression and partially restores sorafenib sensitivity in liver cancer cell. a-b HepG2.215 cells were first treated with or without Akt inhibitor MK-2206, and then further treated with sorafenib. Twenty-four h post sorafenib treatment, a the expression of cIAP2 and cleaved caspase-3 was determined by western blot, and b cell viability was assessed by MTT. For western blot, one representative data out of three is shown. For cell viability, data shown are mean ± SD of three independent experiments. ns, not statistically significant; *, p < 0.05; **, p < 0.01